PepGen Inc.
NASDAQ:PEPGBiotechnology
+$0.09 today
- Market cap
- $265.27M
- Beta
- 1.93
- P/E (TTM)
- -1.6
- EPS (TTM)
- -$1.12
Volume 3.39M
Average 1.37M
PEPG Cost of Revenue
Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.
PepGen Inc.NASDAQ: PEPG
Cost of Revenue · Q1 FY2026 · quarter ended Mar 2026
Cost of revenue remains negative
Q1 FY2026 cost of revenue was $319K, compared with $0 a year earlier. Trailing-twelve-month cost of revenue was $1.72M.
Context
- Cost of revenue increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly cost of revenue holds near $319K or moves back toward the trailing-twelve-month quarterly average of $429K.
Sources:Income StatementText generated from reported figures; not investment advice.
Cost of Revenue history
USD · from the income statement
- Latest · FY2025
- 1.4M USD
- Year-over-year change
- -7.2%
| Period | Period end | Cost of Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 1.4M | -7.2% |
| FY2024 | 2024-12-31 | 1.51M | +27.1% |
| FY2023 | 2023-12-31 | 1.18M | — |
| FY2022 | 2022-12-31 | 0 | — |
| FY2021 | 2021-12-31 | 0 | — |
Cost of Revenue vs competitors
How PEPG compares with its peers on the latest reported figures
- Peers report in different currencies, so cost of revenue is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +351.6% is the highest of 7, against a peer median of -69.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $32.58M USD | -62.0% | -2.1% | 515.8% | |
| LTM Mar 2026 | $29.7M USD | -64.0% | — | 161.2% | |
| LTM Mar 2026 | $11.58M USD | +18.8% | — | 2205.7% | |
| LTM Mar 2026 | CHF 2.61M CHF | -92.3% | -62.9% | — | |
| LTM Mar 2026 | $2.34M USD | — | — | — | |
| LTM Mar 2026 | $1.72M USD | +351.6% | — | — | |
ELTXElicio Therapeutics, Inc. | LTM Mar 2026 | $289K USD | -75.2% | +2.2% | — |
| LTM Mar 2026 | $149K USD | -99.1% | — | — | |
| Peer median (excluding PEPG) | — | -69.6% | -2.1% | 515.8% | |
Competitors are the stored peer set for PEPG. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 1.18M | 1.51M | 1.4M |
| Gross Profit | 0 | 0 | (1.18M) | (1.51M) | (1.4M) |
| Gross Margin | — | — | — | — | — |
| Research & Development | 23.8M | 54.08M | 68.13M | 76.48M | 71.04M |
| Selling, General & Admin | 8.11M | 14.22M | 16.64M | 21.26M | 22.57M |
| Operating Expenses | 27.11M | 68.3M | 83.58M | 96.23M | 92.22M |
| Depreciation & Amortization | 178K | 493K | 1.18M | 1.51M | 1.4M |
| EBITDA | (27.1M) | (64.91M) | (77.37M) | (89.09M) | (88.21M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (27.11M) | (68.3M) | (84.77M) | (97.74M) | (93.61M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 0 | 2.79M | 6.4M | 7.14M | 4.02M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | (172K) | 2.9M | 6.21M | 7.14M | 4.01M |
| Income Before Tax | (27.28M) | (65.4M) | (78.55M) | (90.6M) | (89.61M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 3.71M | 73K | (617K) | 49K |
| Net Income | (27.28M) | (69.1M) | (78.63M) | (89.98M) | (89.66M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (1.22) | (4.42) | (3.30) | (2.85) | (2.12) |
| EPS (Diluted) | (1.22) | (4.42) | (3.30) | (2.85) | (2.12) |
| Weighted Avg Shares | 22.39M | 15.64M | 23.8M | 31.58M | 42.22M |
| Weighted Avg Shares (Diluted) | 22.39M | 15.64M | 23.8M | 31.58M | 42.22M |
PepGen Inc.
NASDAQ:PEPG
Intrinsic Alpha fair value
Locked
Current Price
$3.83
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.